<DOC>
	<DOCNO>NCT01380249</DOCNO>
	<brief_summary>This phase I study adult patient advance solid tumour design evaluate toxicity , drug exposure ( pharmacokinetics ) drug action ( pharmacodynamics ) new molecule , PDM08 , administer twice week cycle 4 week . This drug show antitumoral activity several murine cancer model .</brief_summary>
	<brief_title>PDM08 Clinical Trial Advanced Solid Tumors</brief_title>
	<detailed_description>Phase I study , open , dose escalation , adult patient advance solid tumour , evaluate tolerability , pharmacokinetics pharmacodynamics ascend PDM08 dos administer twice week cycle 4 week . After check safety first drug dos , new dose escalation propose approved Ethic Committee Medicines Agency . This clinical trial carry adult patient advance solid tumour whose disease progress despite standard therapy , standard antineoplastic therapy , refractory . In pharmacodynamic non clinical study , PDM08 present antitumour activity different tumour model include , renal , colon , lung , prostate breast cancer model .</detailed_description>
	<criteria>Population : Adult patient advance solid tumour whose disease progress despite standard therapy , standard antineoplastic therapy , refractory . Informed consent must obtain patient , accordance guideline Good Clinical Practice ( GCP ) International Conference Harmonization ( ICH ) local requirement . Malignant tumour , histologically cytologically demonstrate . Patients age equal great 18 year . Patients must ECOG &gt; 2 ( ECOG 2 : Ambulatory capable selfcare unable carry work activity . Up 50 % waking hour ) The life expectancy patient superior 3 month . Bilirubin &lt; 1,5 time laboratory upper limit . AST ALT less 2,5 time laboratory upper limit , In case liver metastases value le 5 time laboratory upper limit . Women fertile age : pregnant test must carry . Men woman fertile age must commit practice one method birth control participation trial , 30 day administration last dose experimental drug . The patient renal function parameter ( creatinine ) exceed 1.5 time normal upper limit . The patient must present hemoglobin &gt; 9 mg/dL . The patient must show basal platelet count &gt; 100.000 /mm3 . Specific criterion : Patients include expansion cohort must present measurable disease RECIST criterion 1.1 , disease progression last 6 month . Patients agree enter pharmacodynamic tumour tissue substudy present accessible tissue carry biopsy safely . Patients receive chemotherapy , radiotherapy , immunotherapy investigational drug disease within 4 week prior PDM08 first dose . Patients surgery within 4 week treatment . Patients untreated brain metastasis . Patients pregnant breastfeeding . Those patient present intercurrent noncontrolled disease include , limited , active infection , cicatrization problem , congestive heart failure , unstable angina , cardiac arrhythmia , pulmonary disease non control symptom , non control psychiatric disorder social situation may affect compliance requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Phase I multiple dos</keyword>
	<keyword>PDM08</keyword>
	<keyword>Cancer Treatment</keyword>
	<keyword>Pharmacokinetics Pharmacodynamics</keyword>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>Prodimed</keyword>
</DOC>